Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Read more
NovaGo Therapeutics Raises CHF 10 Million to Develop Regenerative Anti-Nogo Therapy for Stroke Read more
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China Read more
Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control Read more
AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes Read more